Publications

• California Judge Allows Public Nuisance Claims Against Social Media Companies
  22 November 2024
  Lindsay Cooper Hayman
  ,
  Maura Kathleen Monaghan
  ,
  John (Jay) Neukom
  ,
  Abraham Tabaie
  ,
  Barbara N. Barath
  ,
  Carter Burwell
  ,
  Jacob W. Stahl
  ,
  Kaitlyn McGill
  ,
  Allison Miller
• Westlaw: The Death of Chevron: Implications of the Loper Decision for Public Companies
  17 September 2024
  Westlaw
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• MarketCheck – Summer 2024
  August 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Jyotin Hamid
  ,
  Emily F. Huang
  ,
  Stephen M. Jordan
  ,
  Maurizio Levi-Minzi
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Jeffrey J. Rosen
  ,
  Zachary H. Saltzman
  ,
  Shannon Rose Selden
  ,
  Matthew J. Sorensen
  ,
  Katherine Durnan Taylor
  ,
  Alison E. Buckley-Serfass
  ,
  Caroline P. Geiger
  ,
  Caitlin Gibson
  ,
  Anne-Mette Heemsoth
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jillian Mulroy Wright
  ,
  Ilya Balabanovsky
  ,
  Marisa Demko
  ,
  Katrina Mari Kaczynski
  ,
  Rekha Korlipara
• 2024 Private Equity Midyear Outlook
  August 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Christopher Dortschy
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Andrew J. Gershon
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Arian M. June
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Gregory J. Lyons
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Sheena Paul
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Paul D. Rubin
  ,
  Scott B. Selinger
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Rick Sofield
  ,
  Katherine Durnan Taylor
  ,
  Ramya S. Tiller
  ,
  Jonathan R. Tuttle
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Jennifer Wheater
  ,
  Naomi Aoyama
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Zhiyan Cao
  ,
  Jennifer R. Cestaro
  ,
  Robert T. Dura
  ,
  Paul Eastham
  ,
  Stuart Hammer
  ,
  Lauren P. Heller
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Michael P. McGuigan
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  John Young
  ,
  Ulysses Smith
  ,
  Kayleigh Anderson
  ,
  Hymie A. Anteby
  ,
  Jabari Benjamin
  ,
  Charles Cartiglia
  ,
  Josephine Chen
  ,
  Jordan Corrente Beck
  ,
  Tejas N. Dave
  ,
  Julia Glazer
  ,
  Michael C. Godbe
  ,
  Zoe Jacoby
  ,
  Yiran Ji
  ,
  Adriana Kranjac
  ,
  Paul D. Lowry
  ,
  Kaitlyn McGill
  ,
  Diana Moise
  ,
  Amy Pereira
  ,
  John M. Satira
  ,
  Eike Björn Weidner
  ,
  Keith Moshe
• Law360: After Chevron: FDA Regulations In The Crosshairs
  8 July 2024
  Law360
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• Increased FCA Enforcement Targeting PE Firms Expected in 2024
  11 March 2024
  Helen V. Cantwell
  ,
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Shannon Rose Selden
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Kaitlyn McGill
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac
  ,
  Kaitlyn McGill
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Ilya Balabanovsky
  ,
  Margaret Howard
  ,
  Chaim Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• Law360: What Banks Should Know About TCPA Exam Policy Updates
  13 December 2023
  Law360
  Maura Kathleen Monaghan
  ,
  Caroline N. Swett
  ,
  Jacob W. Stahl
• OCC Issues Revised TCPA Examination Procedures: What Bank Compliance Personnel Should Know
  15 November 2023
  Helen V. Cantwell
  ,
  Courtney M. Dankworth
  ,
  Maura Kathleen Monaghan
  ,
  Caroline N. Swett
  ,
  Jacob W. Stahl
  ,
  Emma Macfarlane
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• 2023 Private Equity Midyear Outlook
  27 July 2023
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Jeffrey P. Cunard
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Andrew J. Gershon
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Emily F. Huang
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  Rafael Kariyev
  ,
  Meir D. Katz
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Julie M. Riewe
  ,
  Shannon Rose Selden
  ,
  Steven J. Slutzky
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  J. Michael Snypes, Jr.
  ,
  Patrick Taylor
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Erica S. Weisgerber
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Zhiyan Cao
  ,
  Robert T. Dura
  ,
  Stuart Hammer
  ,
  Megan McGuiggan
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Jacob W. Stahl
  ,
  Sergio Torres
  ,
  Jennifer Wheater
  ,
  Elie J. Worenklein
  ,
  Adam Aukland-Peck
  ,
  Colleen B. Bernaiche
  ,
  Charles Cartiglia
  ,
  Paul Eastham
  ,
  Jay E. Evans
  ,
  Sara Ewad
  ,
  Christopher Gossage
  ,
  Camila Isern
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Rekha Korlipara
  ,
  Adriana Kranjac
  ,
  Samuel D. Krawiecz
  ,
  Harshil Mehta
  ,
  Gianni Pizzitola
  ,
  Stanley G. Seckler
  ,
  Sheng Shao
  ,
  Massy Vainshtein
• Legal Dispute Surrounding Abortion Pill Has Significant Implications for Broader Healthcare Industry
  9 May 2023
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Melissa Runsten
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Samuel J. Allaman
  ,
  Adam Aukland-Peck
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Adrian St. Francis
  ,
  Emily G. Dennan
  ,
  Micah A. Rubin
• Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
  November 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
  19 August 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Recent SCOTUS Decisions Impacting Healthcare
  3 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
  16 June 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Adriana Kranjac
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• 2021/2022 Private Equity Year-End Review and Outlook
  January 2022
  Jonathan Adler
  ,
  Catherine Amirfar
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Ezra Borut
  ,
  Andrew J. Ceresney
  ,
  Jennifer L. Chu
  ,
  Jeffrey P. Cunard
  ,
  Alexander R. Cochran
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Morgan J. Hayes
  ,
  Eric T. Juergens
  ,
  Maurizio Levi-Minzi
  ,
  Nicholas P. Pellicani
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Scott B. Selinger
  ,
  Marc Ponchione
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Marshal L. Bozzo
  ,
  Christopher Dortschy
  ,
  Andrew J. Gershon
  ,
  Emily F. Huang
  ,
  Jennifer Wheater
  ,
  Dominic Blaxill
  ,
  Charles Cartiglia
  ,
  Robert T. Dura
  ,
  Matthew J. Sacco
  ,
  Sheng Shao
  ,
  Sergio Torres
  ,
  Charlotte A. Walkovik
  ,
  Paul Eastham
  ,
  Christopher Gossage
  ,
  Robert B. Kaplan
  ,
  Sheena Paul
  ,
  John Young
  ,
  Jin-Hyuk Jang
  ,
  Lukas Ott
  ,
  Andrew M. Levine
  ,
  Stuart Hammer
  ,
  Ulysses Smith
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Peter J. Irwin
  ,
  Ina C. Popova
  ,
  Samantha J. Rowe
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Paul D. Rubin
  ,
  Eric Dinallo
  ,
  Marilyn A. Lion
  ,
  Jacob W. Stahl
  ,
  Nicholas F. Potter
  ,
  Kim T. Le
  ,
  Adam Aukland-Peck
  ,
  Melissa Runsten
  ,
  Matthew Mrozek
  ,
  Michael C. Godbe
  ,
  Christel Y. Tham
  ,
  Lisa Wang Lachowicz
  ,
  Yiran Ji
• 2021 Private Equity Midyear Review and Outlook
  22 July 2021
  Jonathan Adler
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Megan K. Bannigan
  ,
  Sally Bergmann Hardesty
  ,
  David H. Bernstein
  ,
  Paul S. Bird
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Jennifer L. Chu
  ,
  Matthew Dickman
  ,
  Christopher Dortschy
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Peter A. Furci
  ,
  Avi Gesser
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Meir D. Katz
  ,
  Rafael Kariyev
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Paul D. Rubin
  ,
  Zachary H. Saltzman
  ,
  Kevin M. Schmidt
  ,
  Shannon Rose Selden
  ,
  Scott B. Selinger
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Richard Ward
  ,
  Patricia Volhard
  ,
  Franci J. Blassberg
  ,
  Jeffrey P. Cunard
  ,
  Andrew J. Gershon
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Kim T. Le
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jennifer Wheater
  ,
  John Young
  ,
  Adam Aukland-Peck
  ,
  Dominic Blaxill
  ,
  Charles Cartiglia
  ,
  Robert T. Dura
  ,
  Paul Eastham
  ,
  Jay E. Evans
  ,
  David J. Hotelling
  ,
  Samuel D. Krawiecz
  ,
  Wen-Wei Lai
  ,
  Robert Maddox
  ,
  Sergio Torres
  ,
  Malina Welman
• The Supreme Court TransUnion Case: Part 2—What It Means for Efforts to Defeat Class Certification?
  9 July 2021
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Benjamin Leb
• Law360: Lessons From Federal Fraud Charges Against UBiome
  16 April 2021
  Law360
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Hannah R. Levine
• Law360: TCPA Litigation And Compliance After Facebook Ruling
  13 April 2021
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• The Supreme Court Rules for Facebook: What It Means for TCPA Compliance and Class Certification Defense
  7 April 2021
  Courtney M. Dankworth
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• Pharm Exec: The American Rescue Plan Act of 2021: Pharmaceutical Industry Impact
  23 March 2021
  Pharm Exec
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Benjamin Leb
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Eleventh Circuit Precludes “Administrative Feasibility” but Provides a Path Forward for Defendants Opposing Class Certification in Consumer Class Actions
  9 February 2021
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• 2020/2021 Private Equity Year End Review and Outlook
  7 January 2021
  Jonathan Adler
  ,
  William D. Regner
  ,
  John W. Rife III
  ,
  Jennifer R. Cestaro
  ,
  Katherine Ashton
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Christopher Anthony
  ,
  Kevin M. Schmidt
  ,
  Maurizio Levi-Minzi
  ,
  Geoffrey P. Burgess
  ,
  Dominic Blaxill
  ,
  Wen-Wei Lai
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Steven J. Slutzky
  ,
  Richard Ward
  ,
  Jennifer Wheater
  ,
  Paul Eastham
  ,
  Peter A. Furci
  ,
  Rafael Kariyev
  ,
  Jay E. Evans
  ,
  Samuel D. Krawiecz
  ,
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Jyotin Hamid
  ,
  Meir D. Katz
  ,
  Jonathan F. Lewis
  ,
  Tricia Bozyk Sherno
  ,
  Ezra Borut
  ,
  Jeffrey P. Cunard
  ,
  Marc Ponchione
  ,
  Kenneth J. Berman
  ,
  Patricia Volhard
  ,
  Christopher Dortschy
  ,
  Jin-Hyuk Jang
  ,
  John Young
  ,
  Andrew J. Ceresney
  ,
  Robert B. Kaplan
  ,
  Julie M. Riewe
  ,
  Sally Bergmann Hardesty
  ,
  Scott B. Selinger
  ,
  Stuart Hammer
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Jim Pastore
  ,
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Peter J. Irwin
  ,
  Malina Welman
  ,
  Paul S. Bird
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jennifer L. Chu
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Federal Government Shines Spotlight on Speaker Programs
  20 November 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Law360: Trump's Drug Pricing Order Is More Bark Than Bite
  22 September 2020
  Law360
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Providers, Investors Need Clear Post-COVID Telehealth Picture
  22 September 2020
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Bloomberg Law: Providers, Investors Need Clear Post-Covid Telehealth Picture
  16 September 2020
  Bloomberg Law
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Kim T. Le
• Bloomberg Law: Providers, Investors Need Clear Post-Covid Telehealth Picture
  16 September 2020
  Bloomberg Law
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Kim T. Le
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
  29 July 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Supreme Court Acts Twice on the TCPA: What It Means for Automated Callers, the First Amendment, and Statutory Challengers
  10 July 2020
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Jared I. Kagan
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Update Regarding Public Health and Social Services Emergency Fund
  6 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: CMS Expands Medicare Coverage for Telehealth Services amid Public Health Emergency
  20 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: FDA Developments and Legal Considerations for Healthcare and Life Science Companies and Investors
  17 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Suchita Mandavilli Brundage
  ,
  Melissa Runsten
• What the Bipartisan Budget Agreement Means for the Healthcare Industry and Life Sciences Companies
  23 December 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Leah Martin
• Delaware Court of Chancery Sustains Failure to Monitor Caremark Claim
  22 October 2019
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jonathan R. Tuttle
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Congressional Investigation Highlights Potential Risks for Private Equity Healthcare Investments
  19 September 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Maura Kathleen Monaghan
  ,
  David A. O'Neil
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Jacob W. Stahl
• Court Strikes Down Regulation Requiring Price Disclosure in TV Ads for Prescription Drugs
  11 July 2019
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Jyotin Hamid
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS Issues Final Rule Requiring Disclosure of Drug and Biologic “List Prices” in Television Advertisements: Challenges Associated with Lanham Act Enforcement and First Amendment Implications
  16 May 2019
  David H. Bernstein
  ,
  Jyotin Hamid
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Affordable Care Act Likely to Survive Latest Challenge
  19 December 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Life Sciences Companies Can Prepare For Legal And PR Crises
  13 December 2018
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Life Sciences Cos. Can Prepare For Legal And PR Crises
  December 13, 2018
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Medical Device Cybersecurity Report Advancing Coordinated Vulnerability Disclosure
  4 December 2018
  Luke Dembosky
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Managing the Minefield: How Life Sciences Companies Can Be Prepared for Legal and Public Relations Crises
  30 November 2018
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The SEC/FDA Nexus: Best Practices for Publicly Traded Life Sciences Companies
  19 November 2018
  Bloomberg Law
  Andrew J. Ceresney
  ,
  Maura Kathleen Monaghan
  ,
  Paul M. Rodel
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• New Congress Brings Heightened Risk of Investigations for Life Sciences Companies
  19 November 2018
  David A. O'Neil
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• A Post-Election Survey Of The Health Care Ecosystem
  9 November 2018
  Law360
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The 2018 Elections: Winners and Losers in the Healthcare Ecosystem
  9 November 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Part B Price Controls: Hurdles and Unintended Consequences
  5 November 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Rule Regarding Disclosure of Drug “List Prices” in Television Ads: Needed Transparency or Recipe for Confusion?
  23 October 2018
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• Fourth Circuit Decision Casts Doubt on State Efforts to Regulate Drug Pricing
  18 May 2018
  Bloomberg Law
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The White House’s Drug Pricing “Blueprint”
  18 May 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• D.C. Circuit Court Decision May Help Level the Playing Field for TCPA Defendants
  29 March 2018
  Courtney M. Dankworth
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• DOJ Memorandum Addressing Agency Guidance
  9 March 2018
  Compliance & Enforcement
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• DOJ Memorandum Addressing Agency Guidance
  8 March 2018
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Perpetually Liable? What the California Supreme Court Decision Means for Innovator Pharmaceutical Companies
  22 February 2018
  Toxics Law Reporter
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Latest on the Trump Administration’s Drug Pricing Initiatives
  21 February 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• DOJ Creates Potential Opening For Early Dismissal of False Claims Act Suits
  1 February 2018
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• T.H. v. Novartis: Implications for Companies That Have Sold or Are Considering Selling the Rights to Innovator Drugs
  19 January 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
• A Look At Recent Efforts To Contain Health Care Costs
  5 January 2018
  Law360
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Tax Reform and Other Recent Developments Could Impact the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• New Public and Private Efforts to Contain Healthcare Costs: What it Means for the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Law360: How Tax Reform Could Impact the Health Care Industry
  15 November 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Tax Reform Could Impact The Health Care Industry
  13 November 2017
  Law360
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The “Tax Cuts and Jobs Act” – How It Impacts the Healthcare Industry
  7 November 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Gary M. Friedman
  ,
  Peter A. Furci
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Where Does Healthcare Reform Stand?
  31 October 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• How Section 1332 Waivers Could Impact Health Care Reform
  24 July 2017
  Law 360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Health Care Winners And Losers From The Better Care Act
  29 June 2017
  Law 360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The “Better Care Act”: Winners and Losers in the Healthcare Industry
  28 June 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Senate’s Healthcare Bill – What’s In It?
  28 June 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Supreme Court Limits Forum Shopping, Creates Risk Management Opportunities
  23 June 2017
  Maura Kathleen Monaghan
  ,
  William H. Taft V
  ,
  Jacob W. Stahl
• Finally A Health Care Reform Plan Passes the House – What’s in the Bill and What it Means for the Healthcare Industry
  5 May 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Shining A Light On GOP Plan For Health Care Reform
  7 March 2017
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Just a Bit of Clarity – Recent Developments Shine Some Light on Trump and GOP Plans for Healthcare Reform
  27 February 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• The Outlook For The Pharmaceutical Industry Under Trump
  12 January 2017
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Outlook On Drug Pricing: At What Cost?
  14 December 2016
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Still in the Waiting Room: Outlook for the Healthcare Industry Under the Trump Administration
  15 November 2016
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Gary M. Friedman
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• A Walk in the Park Shouldn’t Lead to Jail Time: Recent Decisions Explain Why Incarceration Is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent
  7 October 2016
  Bloomberg BNA Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Helen V. Cantwell
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• FDA’s New Guidance On Cybersecurity For Medical Devices: Important Lessons For The Entire Healthcare Industry
  25 April 2016
  Bloomberg BNA Health IT Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• Canada Vs. US Product Liability: Recent Developments
  25 January 2016
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Christel Y. Tham
• FDA Publishes Guidance on Postmarket Cybersecurity Risk Management for Medical Device Manufacturers
  25 January 2016
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• Canada Vs. US Product Liability: The Canadian Experience
  22 January 2016
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Christel Y. Tham
• Canada Vs. US Product Liability: The US Experience
  21 January 2016
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Christel Y. Tham
• It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
  12 January 2016
  American Bar Association
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Speedy Returns: The 60-Day Rule
  January 12 2016
  American Bar Association
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Avoiding And Defeating Securities Fraud Actions Against Clinical-Stage Biopharmaceutical Companies
  10 July 2015
  Bloomberg BNA Life Sciences Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  William H. Taft V
  ,
  Jacob W. Stahl
• Food For Thought: Corporate Executives On Notice That DOJ Will Seek To Hold Them Criminally Liable for Contaminated Food Outbreaks And Product Failures
  14 November 2014
  Bloomberg BNA’s White Collar Crime Report
  Helen V. Cantwell
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
  14 November 2014
  Bloomberg BNA’s Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• DOJ Proposal Shows Focus on Individuals in Corporate Crime
  30 September 2014
  Law360
  Helen V. Cantwell
  ,
  Matthew E. Fishbein
  ,
  Mark P. Goodman
  ,
  Mary Beth Hogan
  ,
  Andrew M. Levine
  ,
  Jonathan R. Tuttle
  ,
  Bruce E. Yannett
  ,
  Kristin D. Kiehn
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• Provocative DOJ Proposal Aims to Hold Financial Services Executives Criminally Liable, Even Absent Criminal Intent
  22 September 2014
  Bruce E. Yannett
  ,
  Mary Beth Hogan
  ,
  Helen V. Cantwell
  ,
  Matthew E. Fishbein
  ,
  Mark P. Goodman
  ,
  Andrew M. Levine
  ,
  Jonathan R. Tuttle
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments
  17 September 2014
  Bloomberg BNA’s Health Care Fraud Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• FDA Issues Proposed Guidance on Social Media and Internet Communications for Pharmaceutical and Medical Device Manufacturers
  27 June 2014
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• To File or Not to File: the Forum Non Conveniens Dilemma
  May 2014
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor
  4 April 2014
  Bloomberg BNA’s Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Enforcement without Guidance: The FDA’s Policing of Online Pharmaceutical Advertisements and Communications
  20 December 2013
  Bloomberg BNA Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Funding in Focus: When Healthcare Licensing Goes Wrong
  Issue Seven, 2018
  Mark P. Goodman
  ,
  Henry Lebowitz
  ,
  Megan K. Bannigan
  ,
  Jacob W. Stahl